Skip to main content

Table 2 Univariate, multivariate cox proportional hazards regression in the PSM cohort. (n = 220)

From: Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage

 

Overall survival

Disease-free survival

univariate

multivariate

univariate

multivariate

HR

(95%CI)

p value

HR

(95%CI)

p value

HR

(95%CI)

p value

HR

(95%CI)

p value

Treatment

 S-1

1

     

1

     

 XELOX

0.71

0.40–1.26

0.240

   

0.65

0.39–1.09

0.101

   

Age (years)

  < 65

1

  

1

  

1

     

  ≥ 65

1.93

1.11–3.35

0.02

1.33

0.72–2.46

0.363

1.58

0.96–2.60

0.07

   

Sex

 Female

1

     

1

     

 Male

1.14

0.64–2.04

0.66

   

1.25

0.85–2.11

0.393

   

ECOG

 0

1

  

1

  

1

  

1

  

  ≥ 1

2.32

1.31–4.12

0

1.54

0.80–3.00

0.198

2.17

1.28–3.66

0

1.72

0.99–2.98

0.051

ASA

 1 to 2

1

     

1

     

  ≥ 3

0.85

0.58–1.26

0.420

   

1.1

0.85–1.43

0.462

   

Location

 Other

1

     

1

     

 EGJ

0.54

0.13–2.23

0.398

   

2.82

0.88–9.01

0.081

   

T stage

 T1,T2

1

     

1

     

 T3,T4

3.19

0.78–13.12

0.108

   

2.65

0.83–8.47

0.1

   

N stage

 N0,1,2

1

1

 

1

  

1

  

1

  

 N3

1.69

1.37–2.09

< 0.001

1.4

1.09–1.80

0.009

1.54

1.29–1.84

< 0.001

1.26

1.00–1.58

0.05

LNR group

 LNR0,1,2

1

  

1

  

1

  

1

  

 LNR3

1.7

1.41–2.04

< 0.001

1.36

1.09–1.70

0.006

1.67

1.41–1.97

< 0.001

1.44

1.16–1.78

0

Tumor size

  < 6

1

  

1

  

1

  

1

  

  ≥ 6

1.95

1.13–3.39

0.02

1.07

0.97–1.18

0.209

1.91

1.16–3.13

0.01

1.049

0.96–1.15

0.288

Differntiation

 Well to moderately

1

     

1

     

 Poorly

0.81

0.44–1.51

0.512

   

0.95

0.53–1.69

0.855

   

Lauren classification

 Intestinal

1

     

1

     

 Diffuse/Mixed

0.94

0.70–1.26

0.681

   

0.99

0.75–1.30

0.923

   

Lymphovascular invasion

 no

1

     

1

     

 yes

3.13

0.76–12.88

0.114

   

2.53

0.79–8.07

0.117

   

Perineural invasion

 no

1

  

1

  

1

  

1

  

 yes

2.72

1.36–5.43

0.01

2.39

1.18–4.82

0.015

2.05

1.15–3.66

0.02

1.47

0.81–2.66

0.205

Chemotherapy completion

 no

1

  

1

  

1

  

1

  

 yes

0.43

0.24–0.77

0

0.5

0.28–0.91

0.023

0.36

0.21–0.59

< 0.001

0.36

0.21–0.61

< 0.001

CEA (before surgery)

 normal

1

     

1

     

 elevated

1.31

0.32–5.38

0.711

   

1.02

0.25–4.19

0.975

   

CEA (after surgery)

 normal

1

     

1

     

 elevated

1.14

0.28–4.68

0.86

   

0.91

0.22–3.74

0.902

   

CA 19–9 (before surgery)

 normal

1

     

1

  

1

  

 elevated

1.87

0.84–4.16

0.123

   

2.66

1.36–5.24

0.01

1.81

0.88–3.74

0.107

CA 19–9 (after surgery)

 normal

1

     

1

     

 elevated

1.32

0.32–5.41

0.705

   

2.09

0.65–6.67

0.213

   
  1. Univariate analysis and multivariate survival analysis were performed using Cox proportional hazard model, and P values < 0.05 were considered to indicate statistical significance
  2. Abbreviations: CI confidence interval, HR hazard ratio. Significant values are in boldface type
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us